MX2023007444A - Parapoxvirus modificado que tiene inmunogenicidad incrementada. - Google Patents

Parapoxvirus modificado que tiene inmunogenicidad incrementada.

Info

Publication number
MX2023007444A
MX2023007444A MX2023007444A MX2023007444A MX2023007444A MX 2023007444 A MX2023007444 A MX 2023007444A MX 2023007444 A MX2023007444 A MX 2023007444A MX 2023007444 A MX2023007444 A MX 2023007444A MX 2023007444 A MX2023007444 A MX 2023007444A
Authority
MX
Mexico
Prior art keywords
parapoxvirus
modified parapoxvirus
increased immunogenicity
modified
vector
Prior art date
Application number
MX2023007444A
Other languages
English (en)
Inventor
Ralf Amann
Ferdinand Salomon
Original Assignee
Prime Vector Tech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prime Vector Tech Gmbh filed Critical Prime Vector Tech Gmbh
Publication of MX2023007444A publication Critical patent/MX2023007444A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un Parapoxvirus modificado, preferentemente un vector de Parapoxvirus, que tiene una inmunogenicidad incrementada, una célula biológica que contiene este Parapoxvirus modificado, una composición farmacéutica, preferentemente una vacuna, que contiene este vector de Parapoxvirus modificado y/o esta célula, y un nuevo uso de este Parapoxvirus modificado.
MX2023007444A 2020-12-21 2021-12-14 Parapoxvirus modificado que tiene inmunogenicidad incrementada. MX2023007444A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20216198.0A EP4014991A1 (en) 2020-12-21 2020-12-21 Modified parapoxvirus having increased immunogenicity
PCT/EP2021/085774 WO2022136033A1 (en) 2020-12-21 2021-12-14 Modified parapoxvirus having increased immunogenicity

Publications (1)

Publication Number Publication Date
MX2023007444A true MX2023007444A (es) 2023-07-03

Family

ID=73856481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007444A MX2023007444A (es) 2020-12-21 2021-12-14 Parapoxvirus modificado que tiene inmunogenicidad incrementada.

Country Status (13)

Country Link
EP (2) EP4014991A1 (es)
JP (1) JP2024500167A (es)
KR (1) KR20230122630A (es)
CN (1) CN117015609A (es)
AR (1) AR124384A1 (es)
AU (1) AU2021408377A1 (es)
CA (1) CA3202003A1 (es)
CL (1) CL2023001816A1 (es)
CO (1) CO2023008292A2 (es)
IL (2) IL303878A (es)
MX (1) MX2023007444A (es)
TW (1) TW202239428A (es)
WO (1) WO2022136033A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023233007A1 (en) * 2022-06-02 2023-12-07 Eberhard Karls Universität Tübingen Medizinische Fakultät Sars-cov-2 vaccines and uses thereof

Also Published As

Publication number Publication date
WO2022136033A1 (en) 2022-06-30
JP2024500167A (ja) 2024-01-04
IL303876A (en) 2023-08-01
CN117015609A (zh) 2023-11-07
AR124384A1 (es) 2023-03-22
IL303878A (en) 2023-08-01
CO2023008292A2 (es) 2023-07-21
TW202239428A (zh) 2022-10-16
CA3202003A1 (en) 2022-06-30
KR20230122630A (ko) 2023-08-22
AU2021408377A1 (en) 2023-06-29
EP4153231A1 (en) 2023-03-29
CL2023001816A1 (es) 2024-01-12
EP4014991A1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
MX2020004578A (es) Composiciones de casz y metodos de uso.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
BR112017014060A2 (pt) composições de bacillus licheniformis rti184 e métodos de uso para beneficiar o crescimento de plantas
WO2017191274A3 (en) Rna encoding a therapeutic protein
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
CA3057899A1 (en) Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
WO2018143552A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
TW201612190A (en) Flavivirus virus like particle
CO2019010062A2 (es) Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens
CL2023001816A1 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada
MX2023003199A (es) Vacuna contra la enfermedad por coronavirus de 2019 (covid-19) basada en el virus de la parainfluenza 5 (piv5).
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
MX2022011077A (es) Variantes de transglutaminasa.
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
MX2023007376A (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada.
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
MX2020006476A (es) Vacuna contra el virus de lassa.
MX2023007375A (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada.
NZ595060A (en) Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
MX2023012707A (es) Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos.
MX2023002080A (es) Vector de poxviridae recombinante que expresa moleculas coestimuladoras.